Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Thioridazine hydrochloride
Drug ID BADD_D02201
Description A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Indications and Usage For the treatment of schizophrenia and generalized anxiety disorder.
Marketing Status approved; withdrawn
ATC Code N05AC02
DrugBank ID DB00679
KEGG ID D00798
MeSH ID D013881
PubChem ID 66062
TTD Drug ID D0U1OE
NDC Product Code 51079-566; 51079-567; 0378-0612; 46204-0006; 53489-500; 0378-0614; 51927-1928; 53489-148; 53489-150; 61876-0075; 0378-0618; 51079-565; 53489-149; 0378-0616; 51079-580
UNII 4WCI67NK8M
Synonyms Thioridazine | Thioridazine Hydrochloride | Thioridazine HCL | Thioridazine-Neurazpharm | Thioridazine Neurazpharm | ThioridazineNeurazpharm | Thiozine | Aldazine | Meleril | Mellaril | Melleril | Melleryl | Melleretten | Melzine | Rideril | Sonapax | Apo-Thioridazine | Apo Thioridazine | ApoThioridazine
Chemical Information
Molecular Formula C21H27ClN2S2
CAS Registry Number 130-61-0
SMILES CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal dreams17.15.02.001; 19.02.03.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Akathisia19.06.02.006; 17.01.02.002--
Akinesia17.01.02.003--Not Available
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaemia01.03.02.001--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Aplastic anaemia01.03.03.002--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.010--Not Available
Breast engorgement21.05.05.002; 18.08.02.001--Not Available
Cholestasis09.01.01.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Corneal pigmentation06.06.03.013--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diarrhoea07.02.01.001--
Dry mouth07.06.01.002--
Dyspnoea02.11.05.003; 22.02.01.004--
Ejaculation failure21.03.01.003--Not Available
Electrocardiogram QT prolonged13.14.05.004--
Electrocardiogram T wave inversion13.14.05.007--Not Available
Eosinophilia01.02.04.001--
Erythema23.03.06.001--Not Available
Extrapyramidal disorder17.01.02.007--
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
The 1th Page    1 2 3    Next   Last    Total 3 Pages